Vedolizumab (Entyvio®) for the Treatment of Pyoderma Gangrenosum in a Crohn’s Disease Patient

Groudan, Kevin; Gupta, Kamesh; Singhania, Rohit

doi:10.7759/cureus.12582

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another had active Crohn's disease and failed our treatment and a trial of Vedolizumab (anti‐α4β7—A monoclonal integrin blocker). Vedolizumab has been used to treat pyoderma gangrenosum (PG) associated with IBD with variable success 14 . One patient died of dissemination of mucormycosis, presumably from the PPG wound.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical efficacy of crushed prednisolone and hydrocolloid powder in the primary treatment of peristomal pyoderma gangrenosum and correlation to in vitro drug release data

Pearson,

Prentice,

Lim

et al. 2024

International Wound Journal

View full text Add to dashboard Cite

We evaluated the primary application of crushed prednisolone combined with hydrocolloid powder for clinically diagnosed peristomal pyoderma gangrenosum (PPG). We present our data on this cohort and follow‐up of our previous patients. Of the 23 patients who were commenced on this regime, 18 healed (78%). Twenty‐two patients commenced on this regime as the primary treatment for their PPG, and for one, it was a rescue remedy after failed conventional therapy. Four patients with significant medical comorbidities failed to heal and one had their stomal reversal surgery before being fully healed. The proposed treatment regime for PPG is demonstrated to be effective, inexpensive and able to be managed in the patient's usual home environment. In vitro drug release analysis was undertaken, and data are presented to provide further insights into the efficacy of this regime.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Vedolizumab has been used to treat pyoderma gangrenosum (PG) associated with IBD with variable success. 14 One patient died of dissemination of mucormycosis, presumably from the PPG wound. This patient had been heavily immunosuppressed, and the initial PPG wound biopsy was non-specific.…”

Section: Discussionmentioning

confidence: 99%

Clinical efficacy of crushed prednisolone and hydrocolloid powder in the primary treatment of peristomal pyoderma gangrenosum and correlation to in vitro drug release data

Pearson,

Prentice,

Lim

et al. 2024

International Wound Journal

View full text Add to dashboard Cite

show abstract

“…It binds to α4β7 integrin and blocks interaction with a subset of gastrointestinal-homing T cells [ 139 ]. Four patients with IBD experienced PG improvement while taking vedolizumab [ 140 , 141 ]. Conversely, vedolizumab-induced PG has also been observed in patients with IBD [ 142 , 143 ], including a case improving with granulocyte and monocyte apheresis and prednisolone [ 144 ].…”

Section: Biologicsmentioning

confidence: 99%

Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments

et al. 2022

View full text Add to dashboard Cite

Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target. T helper 17/T helper 1-skewed inflammation and exaggerated inflammasome activation lead to a dysregulated neutrophil-dominant milieu with high levels of tumor necrosis factor-α, interleukin (IL)-1β, IL-1α, IL-8, IL-12, IL-15, IL-17, IL-23, and IL-36. Low-evidence studies and a lack of validated diagnostic and response criteria have hindered the discovery and validation of new effective treatments for pyoderma gangrenosum. We review established and emerging treatments for pyoderma gangrenosum. A therapeutic algorithm based on available evidence is also provided. For emerging treatments, we review target molecules and their role in the pathogenesis of pyoderma gangrenosum.

show abstract

A Case of Pyoderma Gangrenosum Complicated with Ulcerative Colitis Successfully Treated by Granulocyte and Monocyte Adsorption Apheresis

HARADA

SHIMOMURA

Sugimoto

et al. 2022

Nishinihon J Dermatol

View full text Add to dashboard Cite

Vedolizumab (Entyvio®) for the Treatment of Pyoderma Gangrenosum in a Crohn’s Disease Patient

Cited by 3 publications

References 10 publications

Clinical efficacy of crushed prednisolone and hydrocolloid powder in the primary treatment of peristomal pyoderma gangrenosum and correlation to in vitro drug release data

Clinical efficacy of crushed prednisolone and hydrocolloid powder in the primary treatment of peristomal pyoderma gangrenosum and correlation to in vitro drug release data

Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments

A Case of Pyoderma Gangrenosum Complicated with Ulcerative Colitis Successfully Treated by Granulocyte and Monocyte Adsorption Apheresis

Contact Info

Product

Resources

About